← ANALYST RATINGS · TIPRANKS
Legend Biotech (LEGN): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy3 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $45.43, the highest $68.00, the lowest $24.00. The average is +145.8% from the last price of $18.48.
Analyst ratings 19
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $20.00 → $20.50+2.5% | Buy | +10.9% | Upgrade | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $19.50+5.4% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $18.50+2.8% | Hold | +0.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.00 → $18.50+2.8% | Hold | +0.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 → $19.50+2.6% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $20.00 → $20.50+2.5% | Buy | +10.9% | Upgrade | 17.10.26on TipRanks 04:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $65.00 | Buy | +251.7% | Reiterated | 14.10.26on TipRanks 10:45 | +7.6%next day +3.7% | ↗ |
| Ziyi Chen★★★★★★★★★★#5523 · hits 45% · avg +3.0% | Goldman Sachs | $39.49 → $38.09−3.5% | Buy | +106.1% | Reiterated | 14.10.26on TipRanks 08:30 | +7.6%next day +3.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $20.50 → $20.00−2.4% | Buy | +8.2% | Upgrade | 13.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.50 → $18.50−5.1% | Hold | +0.1% | Reiterated | 13.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $19.00 → $18.00−5.3% | Hold | −2.6% | Reiterated | 13.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.50 → $18.00−2.7% | Hold | −2.6% | Reiterated | 13.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $20.00 → $19.00−5.0% | Hold | +2.8% | Reiterated | 13.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $20.50 → $20.00−2.4% | Buy | +8.2% | Upgrade | 13.10.26on TipRanks 06:05 | — | |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $74.00 → $68.00−8.1% | Buy | +268.0% | Reiterated | 13.10.26on TipRanks 04:50 | +0.5%next day +7.6% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $35.00 → $33.00−5.7% | Hold | +78.6% | Reiterated | 09.10.26on TipRanks 10:15 | −1.1%next day −4.3% · 5 days +1.2% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $58.00 → $56.00−3.4% | Buy | +203.0% | Reiterated | 08.10.26on TipRanks 09:05 | −1.7%next day −1.1% · 5 days +6.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.50 → $20.50+5.1% | Buy | +10.9% | Upgrade | 03.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $19.50+5.4% | Hold | +5.5% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $19.00+5.6% | Hold | +2.8% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.50 → $18.50+5.7% | Hold | +0.1% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 → $20.00+5.3% | Hold | +8.2% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.50 → $20.50+5.1% | Buy | +10.9% | Upgrade | 03.10.26on TipRanks 05:05 | — | |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $28.00 → $24.00−14.3% | Hold | +29.9% | Assigned | 02.10.26on TipRanks 10:15 | −4.6%next day +0.4% · 5 days −0.9% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $65.00 | Buy | +251.7% | Reiterated | 30.09.26on TipRanks Sep 28 06:45 | −1.8%next day +1.3% · 5 days −0.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.50 | Buy | +5.5% | Upgrade | 21.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 | Hold | +0.1% | Reiterated | 21.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 | Hold | −2.6% | Reiterated | 21.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.50 | Hold | −5.3% | Reiterated | 21.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 | Hold | +2.8% | Reiterated | 21.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.50 | Buy | +5.5% | Upgrade | 21.09.26on TipRanks 06:05 | — | |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $78.00 → $74.00−5.1% | Buy | +300.4% | Reiterated | 11.09.26on TipRanks 05:15 | −3.7%next day −0.1% · 5 days −5.4% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $58.00 | Buy | +213.9% | Reiterated | 09.09.26on TipRanks Sep 10 21:45 | −2.4%next day −3.0% · 5 days −13.5% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $49.00 → $48.00−2.0% | Buy | +159.7% | Reiterated | 12.08.26on TipRanks 08:20 | −5.7%next day −2.5% · 5 days +9.9% | ↗ |
| Ziyi Chen★★★★★★★★★★#5523 · hits 45% · avg +3.0% | Goldman Sachs | $40.50 → $40.70+0.5% | Buy | +120.2% | Reiterated | 12.08.26on TipRanks 08:15 | −5.7%next day −2.5% · 5 days +9.9% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $75.00 → $40.00−46.7% | Hold | +116.5% | Downgrade | 12.08.26on TipRanks 06:30 | −5.7%next day −2.5% · 5 days +9.9% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $29.00 → $24.00−17.2% | Hold | +29.9% | Assigned | 12.08.26on TipRanks Aug 11 16:50 | −5.7%next day −2.5% · 5 days +9.9% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $35.00 | Hold | +89.4% | Initiated | 13.07.26on TipRanks 05:50 | −4.1%next day −0.7% · 5 days −8.9% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $64.00 | Buy | +246.3% | Reiterated | 15.06.26on TipRanks 06:55 | −2.9%next day −5.3% · 5 days −14.9% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $70.00 | Buy | +278.8% | Reiterated | 13.03.26on TipRanks Mar 11 09:06 | +3.8%next day −4.5% · 5 days −8.0% | ↗ |
| James Shin★★★★★★★★★★#4468 · hits 57% · avg +7.3% | Deutsche Bank | $60.00 | Buy | +224.7% | Reiterated | 09.03.26on TipRanks 09:10 | 0.0%next day +2.4% · 5 days +1.2% | ↗ |
| Qize Ding★★★★★★★★★★#7161 · hits 67% · avg +5.5% | Rothschild & Co Redburn | $83.00 → $24.00−71.1% | Hold | +29.9% | Downgrade | 12.02.26on TipRanks 06:50 | −1.0%next day −2.7% · 5 days −0.9% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | $75.00 → $74.00−1.3% | Buy | +300.4% | Reiterated | 17.12.25on TipRanks 08:00 | 0.0%next day −1.4% · 5 days +4.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Legend Biotech
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 02.10.26: target $45.41 at a price of $19.32 (+135.0%); now: $44.01 at $18.48 (+138.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 18 | 17 | 14 | 13 | 11 |
| Buy | 0 | 1 | 1 | 1 | 0 | 0 |
| Hold | 2 | 1 | 3 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.00 (from $-0.05 to $0.07). Last quarter: $0.09.
Sales
Next quarter’s sales estimate — $361M (from $349M to $384M). Last quarter: $388M.
Best top-analyst consensus in the sector · Healthcare
About Legend Biotech
- CEO: Alan S. Bash
- Employees: 3,200
- 2101 Cottontail Lane, Somerset, NJ, 08873, US
- www.legendbiotech.com
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Data from the stock’s TipRanks forecast page, read 34 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗